## Edgar Filing: NEKTAR THERAPEUTICS - Form 4

NEKTAR THER Form 4 September 17, 20											
				CURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						PPROVAL 3235-0287	
Check this boy if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	STATEM Filed pur Section 17(	TEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES d pursuant to Section 16(a) of the Securities Exchange Act of 1934, a 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Estimated burden hou response	urs per		
(Print or Type Respo	onses)										
1			2. Issuer Name <b>and</b> Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]				ng	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O NEKTAR THERAPEUTIC BAY BOULEV	CS, 455 MIS			of Earliest Tr Day/Year) 2015	ransaction			X Director Officer (giv below)	re title109 below)	% Owner ler (specify	
			nendment, Date Original fonth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
	(State)	(Zip)	Tab	la I Non I	Domizzatizza	Soone	itiog A	Person cquired, Disposed	of or Ponoficia	lly Owned	
1.Title of 2. Tr	ansaction Date nth/Day/Year)	2A. Deemo	ed Date, if	3. Transaction Code (Instr. 8)	3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)		5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report or	n a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned di	rectly c	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 12.8	09/15/2015		А	12,500	(1)	09/14/2023	Common Stock	12,500
Restricted Stock Unit	<u>(2)</u>	09/15/2015		А	15,000	(3)	09/14/2023	Common Stock	15,000

## Edgar Filing: NEKTAR THERAPEUTICS - Form 4

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
WANG SUSAN C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158	Х					
Signatures						
Gilbert M. Labrucherie, Jr., Attorney-in-Fact	09/17/2	015				
**Signature of Reporting Person	Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option was granted on September 15, 2015 and vests in equal monthly installments over the one-year period following the grant date.

(2) Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.

(3) This restricted stock unit award vests in full one year following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.